MYELOFIBROSIS IN CHRONIC MYELOPROLIFERATIVE DISORDERS - INCIDENCE AMONG SUBTYPES ACCORDING TO THE HANNOVER CLASSIFICATION

The distribution and the development of fibrosis were evaluated from bone marrow biopsies of patients with chronic myeloproliferative disorders (CMPD), regarding two groups of patients: (1) 564 with follow-up biopsies over a period of up to twelve years observation time, and (2) 1.787 diagnostic bone marrow biopsies from CMPD patients. Fibrosis was divided into three grades of fiber increase: early myelosclerosis, myelofibrosis, and advanced myelofibrosis. The first group of sequential BMB showed a significant progress to myelofibrosis in so-called ''Chronic Megakaryocytic-Granulocytic Myelosis'' - CMGM -, which corresponds to Agnogenic Myeloid Metaplasia - AMM - in 72.4% (21/29 patients), as well as in CML with megakaryocytic increase- CML.MI- in 39.2% (20/51). In the second group of diagnostic biopsies, only 30% of CMGM cases showed no fibrosis. In P. vera, 16.2% (18/111) developed myelofibrosis up to twelve years later. This figure was 4.3% (2/46) in Primary Thrombocythemia. Increase of megakaryocytes in CML indicates a high risk for developing fibrosis, combined with reduced life expectancy.